Compare BridgeBio Pharma Inc (BBIO) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Orion Office REIT Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Orion Office REIT Inc trades at $2.78 (market cap $156.87M). The key difference: BridgeBio Pharma Inc is far larger — about 105.9× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.91% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | ONL | |
|---|---|---|
Market Cap | $16.61B | $156.87M |
Sector | Health | Real Estate |
52-Week High | $90.17 | $3.04 |
52-Week Low | $47.29 | $1.93 |
Enterprise Value | $18.16B | $573.80M |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
ONL trades at $2.82, up 8.46% today, with strong technical indicators showing bullish momentum. The stock shows mixed fundamentals with a low P/B ratio of 0.25 but negative profitability metrics including -65.66% net income margin. Recent Q2 2026 earnings beat expectations with EPS of $0.42 versus -$0.07 forecast, while the company continues strategic portfolio repositioning and maintains a $0.02 dividend payment.
Outlook remains cautious due to persistent net losses and declining revenue trends, though analyst consensus is evenly split between Buy and Hold ratings. Key risks include high debt levels with 39.68% debt-to-asset ratio and ongoing negative cash flow from operations. The technical bullish signal suggests short-term upside potential despite fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
